SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
Description
Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19). In a different context, virus-specific T cells have proven safe and effective. We conducted a randomized (2:1), open-label, phase 1/2 trial to
